Seeking Alpha

Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease

Simufilam Slowed Cognitive Decline by 38% Versus Placebo Over 6 months in Patients with Mild-to-Moderate Alzheimer’s Disease. Drug Effects Favored Mild Alzheimer’s Disease. In Mild Alzheimer’s, ...
Nasdaq

Praxis Precision Medicines Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extension of Essential1 Study for Ulixacaltamide

BOSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
TipRanks on MSN

Soleno Therapeutics announces publication of VYKAT XR study results in JCEM

Soleno Therapeutics (SLNO) announced a publication in the peer-reviewed Journal of Clinical Endocrinology and Metabolism. The paper, titled, ...
Business Insider

Strongbridge Biopharma plc Announces Positive and Statistically Significant Top-Line Results from the Pivotal Phase 3 LOGICS Study of RECORLEV® (levoketoconazole) for the ...

~ LOGICS Study Met Primary Endpoint with High Statistical Significance; Results at the End of the Randomized-Withdrawal Phase of the Study Demonstrated that Withdrawing Patients to Placebo Resulted in ...
The American Journal of Managed Care

Long-Term Efficacy of Baricitinib for Severe Alopecia Areata

Researchers examined the impact of baricitinib withdrawal and retreatment on hair regrowth in patients with severe alopecia areata. Although baricitinib has demonstrated efficacy for treating patients ...
Seeking Alpha

Praxis Precision Medicines Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extension of Essential1 Study for Ulixacaltamide

Sub-study execution confirmed design features for the upcoming Phase 3 program expected to initiate in Q4 2023 BOSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines (PRAX), Inc. (NASDAQ ...